Safety of Intravenous Nicotinamide Riboside Across Multiple Doses in Rats: Preclinical Findings

Synopsis This study evaluated the safety of repeated intravenous nicotinamide riboside (NR) at varying doses in Wistar rats. NR was well-tolerated at 150, 300, and 450 mg/kg, with no adverse effec...

Nicotinamide Riboside and NMN Boost NAD+ Through Microbiota Conversion: Preclinical Findings

Synopsis Using NAD+ metabolomics in mice, this study found that nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are not directly absorbed intact in large amounts. Instead, most or...

Nicotinamide Riboside Protects Against Brain Injury in Intracerebral Hemorrhage: Preclinical Findings

Synopsis Hemorrhagic stroke, caused by bleeding within the brain, is a severe condition with high disability and death rates. This study examined whether nicotinamide riboside (NR)—a vitamin B3–de...

Nicotinamide Riboside Promotes Spinal Cord Repair: Preclinical Findings

Synopsis Repairing the spinal cord after injury is extremely difficult because nerve cells do not easily regenerate. One promising strategy is to activate endogenous neural stem cells (NSCs)—the b...

Niagen® IV (NR IV) Is Safer, Faster, and More Effective Than NAD+ IV at Raising NAD+ Levels

Objectives To assess the safety and efficacy of a single intravenous administration of NR compared to NAD+ and a saline control in terms of whole blood NAD+ changes, tolerable infusion rates, and ...

Effects of Intravenous Nicotinamide Riboside on Doxorubicin-Related Organ Damage: Preclinical Findings

Synopsis Doxorubicin (DOX) is a powerful chemotherapy drug used to treat various cancers, but its use is limited by serious side effects that damage vital organs such as the heart, kidneys, liver,...

Liposome Encapsulation Improves Brain Delivery and Neuroprotective Efficacy of Nicotinamide Riboside in Cerebral Ischemia: Preclinical Findings

Synopsis Although nicotinamide riboside (NR), a vitamin B3–derived NAD+ precursor, has proven neuroprotective effects, its poor ability to cross the blood–brain barrier limits its effectiveness in...

Intravenous Nicotinamide Riboside Protects the Heart from Chemotherapy-Induced Damage: Preclinical Findings

Synopsis Doxorubicin, a widely used chemotherapy drug, is effective against many cancers but often causes dose-dependent heart damage, leading to chronic heart failure. This study evaluated the ca...

Effects of Intravenous Nicotinamide Riboside on Muscle NAD+: Preclinical Findings

Synopsis Although nicotinamide riboside (NR)—a common NAD+ booster—is believed to enhance energy metabolism, clinical studies have shown little effect on muscle function or insulin sensitivity. To...

Nicotinamide Riboside Reduces Heart Damage in Presence of Fentanyl, Midazolam, and Cangrelor: Preclinical Findings

SynopsisWhen blood flow to the heart is blocked and then restored—a process called ischemia-reperfusion injury—cells can be severely damaged. Researchers tested several potential protective compoun...

Nicotinamide Riboside Prevents Gut Damage After Ischemia: Preclinical Findings

Synopsis Acute mesenteric ischaemia happens when blood flow to the intestines is blocked, which can cause tissue damage and even gangrene. This condition is rare but can be life-threatening. Besid...

Tracking NAD+ Production and Breakdown Pathways: Preclinical Findings

Synopsis NAD+ (nicotinamide adenine dinucleotide) is a key molecule for metabolism and is used by important signaling enzymes like PARPs and sirtuins. NAD+ levels decline with age, so scientists a...